Track Ardelyx, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Ardelyx, Inc. ARDX Open Ardelyx, Inc. in new tab

6.12 USD
EPS
-0.24
P/B
10.73
ROE
-39.46
Beta
0.61
Target Price
16.33 USD
Ardelyx, Inc. logo

Ardelyx, Inc.

🧾 Earnings Recap – Q3 2025

Ardelyx demonstrated strong performance in Q3 2025, driven by robust growth in product revenues, particularly from IBSRELA, which saw a 92% year-over-year increase.

  • Total product revenue reached $105.5 million, a 15% increase year-over-year.
  • IBSRELA generated $78.2 million, a record high, with an upward revision of revenue guidance to $270-$275 million for the year.
  • XPHOZAH contributed $27.4 million in revenue, reflecting a 9% increase from the previous quarter.
  • Introduction of ARDX-10531, a next-generation NHE3 inhibitor, marks a significant step in expanding the company’s pipeline.
  • Strong leadership addition with Sue Hohenleitner as CFO, enhancing financial and strategic insights.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 3, 2026
EPS-0.24
Book Value0.60
Price to Book10.73
Debt/Equity157.53
% Insiders3.220%
Growth
Revenue Growth0.28%
Estimates
Forward P/E12.54
Forward EPS0.52
Target Mean Price16.33

DCF Valuation

Tweak assumptions to recompute fair value for Ardelyx, Inc. (ARDX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Ardelyx, Inc. Logo Ardelyx, Inc. Analysis (ARDX)

United States Health Care Official Website Stock

Is Ardelyx, Inc. a good investment? Ardelyx, Inc. (ARDX) is currently trading at 6.12 USD. Market analysts have a consensus price target of 16.33 USD. This suggests a potential upside from current levels.

Earnings Schedule: Ardelyx, Inc. is expected to release its next earnings report on Aug. 3, 2026. The market consensus estimate for Forward EPS is 0.52.

Investor FAQ

Does Ardelyx, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Ardelyx, Inc.?

Ardelyx, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 3, 2026. The company currently has a trailing EPS of -0.24.

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
NGM (Sweden) ARDX

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
July 20, 2021 4.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion